Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials
Authors:
Open Access
- 23 March 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-6
Abstract
Emerging retrospective and prospective studies indicate that immune checkpoint inhibitors (ICIs) can be safe and effective cancer treatments among people living with human immunodeficiency virus (PLWH), however this high-cancer-risk population has often been excluded from groundbreaking cancer ICI trials. Our study aimed to characterize the current rate of exclusion and conditional inclusion of PLWH in cancer ICI trials by tumor type, trial phase, and year. ClinicalTrials.gov cancer ICI trials with planned starts between 1/1/2019 and 10/20/2020 were identified. Based on trial eligibility criteria, trials were categorized as “excluded” if PLWH could not enroll, “conditionally included” if only PLWH with adequate immune function were allowed, or “included/not specified” if HIV was not mentioned in the eligibility criteria. Trials from 2014 were separately collected for comparison over time. The number of trials excluding PLWH were compared to the included/not specified group using Fisher’s exact test. Of 809 trials analyzed from 2019 to 2020, 74.4% excluded, 6.9% conditionally included, and 18.7% included/did not specify PLWH. Early phase trials excluded PLWH more frequently than late phase trials. The 2019–2020 trial cohort showed no significant change in exclusion of PLWH compared to 2014. Despite increasing evidence for safe and effective ICI use for PLWH, most cancer ICI trials exclude PLWH and few studies permit PLWH to participate, even if HIV is well-controlled.Keywords
This publication has 11 references indexed in Scilit:
- Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 StudyJAMA Oncology, 2019
- Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage CancerJAMA Oncology, 2019
- Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- HIV-Associated Cancers and Related DiseasesNew England Journal of Medicine, 2018
- Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage studyThe Lancet HIV, 2017
- Excess Mortality among HIV-Infected Individuals with Cancer in the United StatesCancer Epidemiology, Biomarkers & Prevention, 2017
- Cumulative Incidence of Cancer Among Persons With HIV in North AmericaAnnals of Internal Medicine, 2015
- Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United StatesJournal of Clinical Oncology, 2015
- Non-AIDS-Defining Malignancies in the HIV-Infected PopulationCurrent Infectious Disease Reports, 2014
- Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysisThe Lancet, 2007